Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 220Neoplasms 192Carcinoma, Non-Small-Cell Lung 185Colorectal Neoplasms 129Prostatic Neoplasms 119Lung Neoplasms 107Neoplasm Metastasis 91Multiple Myeloma 89Ovarian Neoplasms 85Pancreatic Neoplasms 78Squamous Cell Carcinoma of Head and Neck 71Leukemia, Myeloid, Acute 70Melanoma 61Stomach Neoplasms 56Recurrence 51Endometrial Neoplasms 50Brain Neoplasms 46Lymphoma 45Carcinoma, Renal Cell 45Carcinoma, Hepatocellular 45Glioblastoma 44Urinary Bladder Neoplasms 43Triple Negative Breast Neoplasms 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Hematologic Neoplasms 40Esophageal Neoplasms 39Lymphoma, Large B-Cell, Diffuse 37Leukemia, Lymphocytic, Chronic, B-Cell 37Head and Neck Neoplasms 37Lymphoma, Non-Hodgkin 36

Interventions

Health Services Needs and Demand 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Advanced Cancer × 30 days × Clear all
NCT06656390 2026-05-22

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Shanghai Allink Biotherapeutics Co., Ltd.

Phase 1/2 Recruiting
202 enrolled
Other solid neoplasm

Advanced Cancer

NCT06616298 2026-05-05

ALIGN

University of Colorado, Denver

Phase NA Recruiting
120 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡